Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's lead product candidate is Maralixibat, an investigational oral drug that is in Phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It is also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. The company was incorporated in 2018 and is headquartered in Foster City, California.
IPO Year: 2019
Exchange: NASDAQ
Website: mirumpharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/18/2026 | $130.00 | Outperform | RBC Capital Mkts |
| 9/24/2025 | $95.00 | Buy | TD Cowen |
| 8/11/2025 | $89.00 | Buy | Stifel |
| 5/19/2025 | $73.00 | Buy | H.C. Wainwright |
| 4/17/2024 | $48.00 | Buy | Stifel |
| 12/18/2023 | $60.00 → $58.00 | Buy | H.C. Wainwright |
| 11/20/2023 | $37.00 | Overweight | Analyst |
| 11/13/2023 | $60.00 | Overweight | Morgan Stanley |
| 10/24/2023 | $50.00 | Overweight | Cantor Fitzgerald |
| 10/17/2023 | $62.00 | Outperform | Evercore ISI |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
144 - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
144 - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
144 - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
144 - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
144 - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
144 - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
S-3ASR - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)
S-8 - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)
10-K - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)
8-K - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
Live FDA approvals issued by the Food and Drug Administration and FDA breaking news
For Immediate Release: February 21, 2025 Today, the U.S. Food and Drug Administration approved Ctexli (chenodiol) for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. Ctexli is the first FDA-approved drug to treat CTX, a very rare lipid storage disease.“The FDA is dedicated to supporting new drug development for rare diseases including very rare metabolic diseases like cerebrotendinous xanthomato
Fastest customizable press release news feed in the world
- Study designed to support potential label expansion into additional settings of cholestatic pruritus - Topline data expected in Q4 2026 Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced completion of enrollment in EXPAND, a Phase 3 randomized, double-blind, placebo-controlled study evaluating LIVMARLI® (maralixibat) for the treatment of cholestatic pruritus in patients aged 6 months or older with rare cholestatic liver diseases, including biliary atresia. Cholestatic liver diseases are characterized by impaired bile flow, resulting in elevated serum bile acids, severe pruritus, and significantly reduced quality of life. While LIVMARLI is appr
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that on March 11, 2026, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 5,400 shares of common stock and 6,800 restricted stock units ("RSUs") to five new employees under Mirum's 2020 Inducement Plan. The Compensation Committee of Mirum's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price of $91.75 per share, which is equal to Mirum's closing trading price on March 11, 2026, a
- Phase 3 AZURE-1 enrollment complete - Phase 3 AZURE-4 screening complete - Topline AZURE-1 and AZURE-4 results expected in 2H 2026 - AZURE-1 and AZURE-4 to form the basis of Mirum's U.S. BLA Submission Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced completion of enrollment in the Phase 3 AZURE-1 study and completion of screening in the Phase 3 AZURE-4 study, both evaluating brelovitug for the treatment of chronic hepatitis delta virus (HDV). Achievement of these milestones confirms the expected timing of topline 24-week data in the second half of 2026. AZURE-1 and AZURE-4 together will form the basis of Mirum's U.S. BLA submission for br
- 2025 net product sales of $521 million - 2026 expected global net product sales of $630 million to $650 million - Volixibat VISTAS study in PSC topline data expected Q2 2026 - LIVMARLI® EXPAND study in additional cholestatic pruritus settings topline data expected Q4 2026 - Brelovitug AZURE-1 and AZURE-4 studies in HDV topline data expected H2 2026 - Conference call to provide business updates today, February 25 at 1:30 p.m. PT/4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today reported financial results for the fourth quarter and year-end 2025 and provided a business update. "2025 was a year of meaningful progress and execution for
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that it will participate in the following upcoming investor conferences: TD Cowen's 46th Annual Health Care Conference: Monday, March 2, 2026 Company fireside chat starting at 1:10 p.m. ET The Citizens Life Sciences Conference: Tuesday, March 10, 2026 Company fireside chat starting at 10:10 a.m. ET Barclays 28th Annual Global Healthcare Conference: Tuesday, March 10, 2026 2026 Leerink Partners Global Healthcare Conference: Wednesday, March 11, 2026 Company fireside chat starting at 10:00 a.m. ET The fireside chats will be webcast live and can be accessed by visiting th
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will report fourth quarter and year-end 2025 financial results on February 25, 2026. Mirum will also host a conference call to discuss the fourth quarter and year-end 2025 financial results and recent corporate progress. Conference call details: Wednesday, February 25, 2026 4:30 p.m. ET / 1:30 p.m. PT Dial-In: US/Toll-Free: +1 833 470 1428 International: +1 646 844 6383 Access Code: 047642 You may also access the call via webcast by visiting the Investors section of Mirum's corporate website. The archived webcast will be available for replay. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals (NASDAQ:MIRM) is a
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that on February 10, 2026, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 163,040 shares of common stock, 219,090 restricted stock units ("RSUs"), and 48,880 performance stock units ("PSUs") to 37 new employees under Mirum's 2020 Inducement Plan. The Compensation Committee of Mirum's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $100.91 per share, Mirum's closing trading price on Febr
- Tablet authorization builds upon established use of LIVMARLI oral solution in Canada Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that Health Canada has authorized the tablet formulation of LIVMARLI® (maralixibat) for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). LIVMARLI had previously been authorized in Canada as an oral solution for the treatment of cholestatic pruritus in patients with ALGS aged 12 months or older. The tablet formulation complements the existing 9.5 mg/ml oral solution, offering an additional dosing option for patients with ALGS weighing 22 kg or more who are able to swallow tablets.
- Authorization includes oral solution and tablet formulation to support flexible dosing Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that Health Canada has authorized LIVMARLI® (maralixibat) oral solution and tablet formulation for the treatment of cholestatic pruritus in patients aged 12 months or older with progressive familial intrahepatic cholestasis (PFIC). PFIC is a rare, inherited pediatric liver disease caused by impaired bile flow, leading to the accumulation of bile acids in the liver and bloodstream. Cholestasis in PFIC is associated with severe pruritus that can significantly impede quality of life for patients and caregivers. L
- Adds brelovitug for chronic hepatitis delta virus (HDV) with Breakthrough Therapy and PRIME designations to Mirum's portfolio - Topline Phase 3 results expected in 2H 2026 Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced the successful completion of its acquisition of Bluejay Therapeutics, a privately held biotechnology company focused on viral and liver diseases. With the completion of the acquisition, Mirum adds worldwide rights to brelovitug, a late-stage, fully human monoclonal antibody for chronic hepatitis delta virus (HDV), a rare and severe liver disease with no FDA-approved therapies in the United States. Brelovitug has received Bre
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
RBC Capital Mkts initiated coverage of Mirum Pharmaceuticals with a rating of Outperform and set a new price target of $130.00
TD Cowen initiated coverage of Mirum Pharmaceuticals with a rating of Buy and set a new price target of $95.00
Stifel resumed coverage of Mirum Pharmaceuticals with a rating of Buy and set a new price target of $89.00
H.C. Wainwright resumed coverage of Mirum Pharmaceuticals with a rating of Buy and set a new price target of $73.00
Stifel initiated coverage of Mirum Pharmaceuticals with a rating of Buy and set a new price target of $48.00
H.C. Wainwright reiterated coverage of Mirum Pharmaceuticals with a rating of Buy and set a new price target of $58.00 from $60.00 previously
Analyst resumed coverage of Mirum Pharmaceuticals with a rating of Overweight and set a new price target of $37.00
Morgan Stanley initiated coverage of Mirum Pharmaceuticals with a rating of Overweight and set a new price target of $60.00
Cantor Fitzgerald initiated coverage of Mirum Pharmaceuticals with a rating of Overweight and set a new price target of $50.00
Evercore ISI resumed coverage of Mirum Pharmaceuticals with a rating of Outperform and set a new price target of $62.00
Live Leadership Updates
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced the appointment of Doug Sheehy, JD, as chief legal officer. Mr. Sheehy brings nearly two decades of experience leading global legal and compliance operations for biopharmaceutical companies. Mr. Sheehy was most recently chief legal officer and secretary at Sonoma Biotherapeutics, Inc., which is developing regulatory T cell therapies for autoimmune and inflammatory diseases. Prior to Sonoma, from 2016 to 2020, he served as general counsel and secretary for Aimmune Therapeutics, Inc., a biopharmaceutical company that specialized in the development and commercialization of treatments for life-threatening food allergies. Mr. Sheehy serv
- 2024 net product sales of approximately $336 million exceeds upper end of guidance range; preliminary and unaudited estimate - 2025 expected global net product sales of $420 million to $435 million - VISTAS study of volixibat in primary sclerosing cholangitis expected to complete enrollment in second half 2025; topline data expected 2026 Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today provided its preliminary and unaudited estimates for full-year 2024 net product sales, year-end cash balance, corporate updates, and full-year 2025 outlook. "2024 marked a significant year for Mirum as we accelerated our commercial business and achieved significant development milestones," said Chris
SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Tim Walbert and Paul Hoelscher, to the board of directors of the Company, effective April 1, 2024. "We are fortunate to have Tim and Paul join us at this key stage as we prepare to initiate a pivotal, Phase 3 trial for our lead candidate denifanstat in MASH in the second half of 2024," said Dave Happel, CEO of Sagimet. "With his experience as CEO of publi
Se NodThera Ltd ("NodThera" or the "Company") NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer BOSTON, MA, February 5, 2024 - NodThera, a leading clinical-stage biotech developing brain-penetrant NLRP3 inhibitors to treat chronic inflammatory diseases, today announces the appointment of Thomas Jaecklin, M.D., M.Sc., FMH as Chief Medical Officer (CMO), with effect from today. With more than 20 years of experience across global large pharma, biotech and academic medicine, Dr. Jaecklin is an accomplished late-stage drug development leader. He brings deep expertise across multiple therapy areas, including neuroscience and inflammation, with a strong track reco
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that in conjunction with the recent appointment of Joanne Quan, MD as Chief Medical Officer, the Compensation Committee of Mirum's Board of Directors approved an inducement grant of non-qualified stock options to purchase 75,000 shares of common stock and 37,500 restricted stock units ("RSUs") under Mirum's 2020 Inducement Plan. The Compensation Committee approved the awards as an inducement material to Dr. Quan's employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $26.72 per share, Mirum's closing trading price on January 16, 2024, and will vest over four years, wi
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), today announced the appointment of Joanne Quan, MD as Chief Medical Officer. Dr. Quan will lead the global clinical development, clinical operations, and safety programs for Mirum's pipeline of programs addressing rare diseases. Dr. Quan was most recently Chief Medical Officer at Nuvig Therapeutics. Prior to Nuvig, she served in the same role at Modis Therapeutics, a company focused on rare genetic diseases (acquired by Zogenix, Inc. and subsequently UCB). Before Modis, she held clinical development leadership positions at Eiger Biopharmaceuticals, InterMune, Arena Pharmaceuticals, Bayhill Therapeutics, ALZA Corporation (Johnson and Johnson), Gen
- $186-188 million in total revenue and $178-180 million net product sales expected for 2023, preliminary and unaudited - LIVMARLI net products sales of $141-143 million expected for 2023, representing approximately 89% year-over-year growth, preliminary and unaudited Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today provided its preliminary and unaudited estimates for full-year 2023 revenue and net product sales, corporate updates, and full-year 2024 outlook. "2023 was a transformative year for Mirum as we cemented our position as a leader in rare disease and dramatically advanced our operating and financial scale. We expanded our reach and impact through strong global adoption of LIVM
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced the appointment of Eric Bjerkholt as chief financial officer (CFO). "Eric is an accomplished CFO bringing an outstanding track record in driving financial performance, business development, and operations management," said Chris Peetz, president and chief executive officer at Mirum. "Eric is joining at an important period of growth and global scale for Mirum, and it is a pleasure to have his experience and leadership at Mirum as we continue to execute on numerous initiatives across our rare disease franchises." Mr. Bjerkholt brings extensive business leadership experience from roles served in the biopharmaceutical industry. He co
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that Tim Walbert has been appointed to the company's Board of Directors. In addition to Mr. Walbert's appointment, the company shared that Niall O'Donnell, Ph.D., a Mirum director since November 2018, has announced his plan to step down from the Board of Directors concurrent with the upcoming 2023 Annual Meeting of Stockholders expected to be held on June 12, 2023. Tim Walbert joins Mirum's board following a 15-year tenure as president, chief executive officer, and chairman of the board of Horizon Therapeutics, which he built from inception to a leading rare disease company. Horizon recently announced its intent to be acquired by A
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced the appointment of Lon Cardon, Ph.D., FMedSci, to its Board of Directors where he will also serve as a member of the Nominating and Governance Committee. Dr. Cardon brings nearly 30 years of extensive industry and academic experience in drug discovery and development. Dr. Cardon currently serves as president and chief executive officer of The Jackson Laboratory. Prior to this role, Dr. Cardon was chief scientific officer and chief scientific strategy officer at BioMarin. Before joining BioMarin, he was a senior vice president at GlaxoSmithKline, leading departments and divisions spanning genetics, molecular biology, computational bi
Live finance-specific insights
- 2025 net product sales of $521 million - 2026 expected global net product sales of $630 million to $650 million - Volixibat VISTAS study in PSC topline data expected Q2 2026 - LIVMARLI® EXPAND study in additional cholestatic pruritus settings topline data expected Q4 2026 - Brelovitug AZURE-1 and AZURE-4 studies in HDV topline data expected H2 2026 - Conference call to provide business updates today, February 25 at 1:30 p.m. PT/4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today reported financial results for the fourth quarter and year-end 2025 and provided a business update. "2025 was a year of meaningful progress and execution for
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will report fourth quarter and year-end 2025 financial results on February 25, 2026. Mirum will also host a conference call to discuss the fourth quarter and year-end 2025 financial results and recent corporate progress. Conference call details: Wednesday, February 25, 2026 4:30 p.m. ET / 1:30 p.m. PT Dial-In: US/Toll-Free: +1 833 470 1428 International: +1 646 844 6383 Access Code: 047642 You may also access the call via webcast by visiting the Investors section of Mirum's corporate website. The archived webcast will be available for replay. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals (NASDAQ:MIRM) is a
-Planned acquisition of brelovitug for chronic hepatitis delta virus (HDV) with Breakthrough Therapy and PRIME designations -Anticipated to be highly synergistic with Mirum's liver expertise and proven global commercial capabilities -HDV: Large, high unmet-need rare liver disease with no FDA-approved therapies -Top-line Phase 3 results expected in 2H 2026 -Conference call today, December 8, 2025 at 8:30 am ET/5:30 am PT Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced its entry into a definitive agreement to acquire Bluejay Therapeutics, a privately held biotechnology company focused on viral and liver diseases. The transaction would add worldw
- Third quarter 2025 total revenue of $133 million - 2025 revenue guidance updated to $500 to $510 million - Phase 2b VISTAS topline data expected second quarter of 2026 - Conference call to provide business updates today, November 4 at 1:30 p.m. PT / 4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today reported financial results for the third quarter 2025 and provided a business update. "Mirum is well positioned heading into 2026 with strong commercial momentum and multiple upcoming catalysts," said Chris Peetz, Chief Executive Officer of Mirum. "Our third quarter results once again underscore the strength of our commercial medicines with continued strong performance. We also
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will report third quarter 2025 financial results on November 4, 2025. Mirum will also host a conference call to discuss the third quarter 2025 financial results and recent corporate progress. Conference call details: Tuesday November 4th, 2025 4:30 p.m. ET / 1:30 p.m. PT Dial-In: US/Toll-Free: +1 833 470 1428 International: +1 646 844 6383 Access Code: 299722 You may also access the call via webcast by visiting the Events & Presentations section on Mirum's website. A replay of this webcast will be available for 30 days. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedica
- Second quarter 2025 total revenue of $128 million - 2025 revenue guidance increased to $490 to $510 million - Conference call to provide business updates today, August 6 at 1:30 p.m. PT / 4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today reported financial results for the second quarter 2025 and provided a business update. "Our second quarter results once again underscore the strength of our commercial programs with notable outperformance from our International business and U.S. PFIC launch," said Chris Peetz, chief executive officer of Mirum. "The momentum we are seeing with Livmarli globally reinforces our belief that the medicine will reach and help more patients tha
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will report second quarter 2025 financial results on August 6, 2025. Mirum will also host a conference call to discuss the second quarter 2025 financial results and recent corporate progress. Conference call details: Wednesday, August 6th, 2025 4:30 p.m. ET / 1:30 p.m. PT Dial-In: U.S./Toll-Free: +1 833 470 1428 International: +1 404 975 4839 Access Code: 448461 You may also access the call via webcast by visiting the Events & Presentations section on Mirum's website. A replay of this webcast will be available for 30 days. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a biopharmaceutical
- First quarter 2025 total revenue of $111.6 million; 2025 guidance increased to $435 to $450 million - VISTAS study in PSC expected to complete enrollment in third quarter of 2025; topline data expected in second quarter of 2026 - LIVMARLI oral tablet formulation FDA approved - Conference call to provide business updates today, May 7 at 1:30 p.m. PT/4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today reported financial results for the first quarter 2025 and provided a business update. "It's been a strong start to the year with commercial growth and multiple milestones achieved across our pipeline," said Chris Peetz, chief executive officer of Mirum. "We're pleased with the FD
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will report first quarter 2025 financial results on Wednesday, May 7, 2025. Mirum will also host a conference call to discuss the first quarter 2025 financial results and recent corporate progress. Conference call details: Wednesday, May 7, 2025 4:30 p.m. ET / 1:30 p.m. PT Dial-in: U.S./Toll-Free: + 1 833 470 1428 International: + 1 404 975 4839 Passcode: 549600 You may also access the call via webcast by visiting the Events & Presentations section on Mirum's website. A replay of this webcast will be available for 30 days. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a biopharmaceutical company d
- 2024 net product sales of $336.4 million - 2025 expected global net product sales of $420 million to $435 million - VISTAS study of volixibat in PSC expected to complete enrollment in second half 2025; topline data expected 2026 - CTEXLI (chenodiol) approved in the US for cerebrotendinous xanthomatosis - Conference call to provide business updates today, February 26 at 1:30 p.m. PT/4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today reported financial results for the fourth quarter and year-end 2024 and provided a business update. "2024 was another year of significant growth and accomplishments for Mirum and in 2025 we expect this momentum to continue," said Chris Pee
This live feed shows all institutional transactions in real time.
SC 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
SC 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
SC 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
SC 13G - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
SC 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
SC 13G - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
SC 13G - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
SC 13D/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
SC 13G - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
SC 13D/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)